Fortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary

• Fortress Biotech Inc FBIO.OQ reported a quarterly adjusted loss of 50 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -73 cents. The mean expectation of two analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -41 cents to -31 cents per share.

• Revenue rose 10.2% to $16.41 million from a year ago; analysts expected $14.53 million.

• Fortress Biotech Inc's reported EPS for the quarter was 45 cents​.

• The company reported quarterly net income of $13.36 million.

• Fortress Biotech Inc shares had risen by 3.8% this quarter and lost 4.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 19.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for Fortress Biotech Inc is $16.00, about 87.9% above its last closing price of $1.93

This summary was machine generated from LSEG data August 14 at 09:10 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)